BIOTON S.A.

BIOTON S.A. Company Introduction:

BIOTON S.A. is a prominent Polish pharmaceutical company established in 1989, headquartered in Warsaw, Poland. The company specializes in the research, development, production, and commercialization of modern medicines, with a strong focus on human insulin and its analogues, as well as other biopharmaceutical products. BIOTON S.A. is recognized for its high-quality manufacturing standards and its commitment to advancing patient health worldwide, particularly in the field of diabetes treatment. Its product portfolio extends across various therapeutic areas.

Factory or Trader:

BIOTON S.A. is fundamentally a pharmaceutical manufacturer (factory) with its main production facilities located in Poland. While BIOTON S.A. is a manufacturer, if it maintains a presence in Singapore, it would most likely operate as a trading entity, a sales office, or a regional distribution center, rather than a manufacturing factory. Its core manufacturing operations are conducted in Poland.

The company BIOTON S.A. is a Polish pharmaceutical company, not a Singaporean one. It specializes in the production and sale of pharmaceutical products, primarily focusing on diabetes treatment. Its products may be available in Singapore through various distribution channels.

The main products manufactured and sold by BIOTON S.A. include:

Human recombinant insulin preparations, such as:

- Gensulin M30: A biphasic human insulin suspension.

- Gensulin R: A soluble human insulin.

- Gensulin N: An isophane human insulin suspension.

These insulin products are typically offered in various forms, including:

- Cartridges for insulin pens.

- Vials for injection.

- Pre-filled pens.

In addition to insulin products, BIOTON S.A. is also involved in the development and sale of other active pharmaceutical ingredients (APIs) and biosimilar products.